{"id":"ido1","name":"IDO1","symbol":"IDO1","route":"/targets/ido1/","asOf":"2026-09-22","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6059","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000131203","uniprot":"https://www.uniprot.org/uniprotkb/P14902/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P14902","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL4685","open-targets":"https://platform.opentargets.org/target/ENSG00000131203","civic":"https://civicdb.org/genes/3620/summary","oncokb":"https://www.oncokb.org/gene/IDO1","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=IDO1","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=IDO1","depmap":"https://depmap.org/portal/gene/IDO1?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000131203-IDO1","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/3620","omim":"https://www.omim.org/entry/147435"}],"products":[{"id":"epacadostat","name":"Epacadostat","status":"negative","modality":"Small molecule (IDO1 inhibitor)","route":"/drugs/epacadostat/"},{"id":"io102-io103","name":"IO102-IO103","status":"phase-3","modality":"peptide (immunotherapeutic vaccine)","route":"/drugs/io102-io103/"}],"trials":[{"id":"nct03260894","name":"Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)","nct":"NCT03260894","phase":"3","status":"completed"},{"id":"nct03358472","name":"Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)","nct":"NCT03358472","phase":"3","status":"completed"},{"id":"nct05155254","name":"IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)","nct":"NCT05155254","phase":"3","status":"active"},{"id":"nct03348904","name":"Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer","nct":"NCT03348904","phase":"3"},{"id":"nct05280314","name":"Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors","nct":"NCT05280314","phase":"2","status":"recruiting"},{"id":"nct03516708","name":"Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer","nct":"NCT03516708","phase":"1/2","status":"recruiting"}],"pathways":[],"companies":["io-biotech","merck"],"keyPapers":["paper-gruosso-tnbc-spatial-immune-microenvironments-jci-2019"],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}